Literature DB >> 7540528

Flare of arthritis with successful treatment of Felty's syndrome with granulocyte colony stimulating factor (GCSF).

S Q Hayat1, M Hearth-Holmes, R E Wolf.   

Abstract

A 58-year-old white male with Felty's syndrome was successfully treated with granulocyte colony stimulating factor (GCSF). GCSF can correct the granulocytopenia of Felty's syndrome and may be a beneficial therapeutic adjunct in patients who have serious infections associated with neutropenia. The patient developed a flare of arthritis concomitant with increased circulating neutrophils following GCSF therapy.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7540528     DOI： 10.1007/bf02214946

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


  10 in total

1.  Granulocyte-colony stimulating factor corrects granulocytopenia in Felty's syndrome.

Authors:  T Ito; Y Miyairi; T Kuwabara; K Dan; T Nomura
Journal:  Am J Hematol       Date:  1992-08       Impact factor: 10.047

2.  Neutropenia of Felty's syndrome successfully treated with granulocyte colony stimulating factor.

Authors:  D D Fraser; G P Sartiano; T W Butler; E L Treadwell
Journal:  J Rheumatol       Date:  1993-08       Impact factor: 4.666

3.  The Felty syndrome and G-CSF-associated thrombocytopenia and severe anemia.

Authors:  T Wun
Journal:  Ann Intern Med       Date:  1993-02-15       Impact factor: 25.391

4.  Correction of granulocytopenia in Felty's syndrome by granulocyte-macrophage colony-stimulating factor. Simultaneous induction of interleukin-6 release and flare-up of the arthritis.

Authors:  B P Hazenberg; M A Van Leeuwen; M H Van Rijswijk; A C Stern; E Vellenga
Journal:  Blood       Date:  1989-12       Impact factor: 22.113

5.  Neutrophils express the high affinity receptor for IgG (Fc gamma RI, CD64) after in vivo application of recombinant human granulocyte colony-stimulating factor.

Authors:  R Repp; T Valerius; A Sendler; M Gramatzki; H Iro; J R Kalden; E Platzer
Journal:  Blood       Date:  1991-08-15       Impact factor: 22.113

6.  GM-CSF in the treatment of Felty syndrome.

Authors:  G Joseph; D H Neustadt; J Hamm; M Kellihan; T Hadley
Journal:  Am J Hematol       Date:  1991-05       Impact factor: 10.047

7.  Reversal of gold-induced neutropenia with granulocyte colony-stimulating factor (G-CSF).

Authors:  D A Collins; J H Tobias; R P Hill; B E Bourke
Journal:  Br J Rheumatol       Date:  1993-06

8.  Involvement of the high-affinity receptor for IgG (Fc gamma RI; CD64) in enhanced tumor cell cytotoxicity of neutrophils during granulocyte colony-stimulating factor therapy.

Authors:  T Valerius; R Repp; T P de Wit; S Berthold; E Platzer; J R Kalden; M Gramatzki; J G van de Winkel
Journal:  Blood       Date:  1993-08-01       Impact factor: 22.113

9.  Synergy of interleukin 3 and tumor necrosis factor alpha in stimulating clonal growth of acute myelogenous leukemia blasts is the result of induction of secondary hematopoietic cytokines by tumor necrosis factor alpha.

Authors:  M A Brach; H J Gruss; Y Asano; S de Vos; W D Ludwig; R Mertelsmann; F Herrmann
Journal:  Cancer Res       Date:  1992-04-15       Impact factor: 12.701

10.  Interactions of granulocyte-macrophage colony-stimulating factor (CSF), granulocyte CSF, and tumor necrosis factor alpha in the priming of the neutrophil respiratory burst.

Authors:  A Khwaja; J E Carver; D C Linch
Journal:  Blood       Date:  1992-02-01       Impact factor: 22.113
  10 in total
  7 in total

Review 1.  Clinical toxicity of cytokines used as haemopoietic growth factors.

Authors:  T Vial; J Descotes
Journal:  Drug Saf       Date:  1995-12       Impact factor: 5.606

Review 2.  Cytokine-induced autoimmune disorders.

Authors:  P Miossec
Journal:  Drug Saf       Date:  1997-08       Impact factor: 5.606

Review 3.  Anti-colony-stimulating factor therapies for inflammatory and autoimmune diseases.

Authors:  John A Hamilton; Andrew D Cook; Paul P Tak
Journal:  Nat Rev Drug Discov       Date:  2016-12-29       Impact factor: 84.694

Review 4.  Emerging immunotherapies for rheumatoid arthritis.

Authors:  Gary Reynolds; Faye A H Cooles; John D Isaacs; Catharien M U Hilkens
Journal:  Hum Vaccin Immunother       Date:  2014-02-17       Impact factor: 3.452

5.  Felty's Syndrome, Insights and Updates.

Authors:  Mohammad Bagher Owlia; Kam Newman; Mojtaba Akhtari
Journal:  Open Rheumatol J       Date:  2014-12-31

6.  C5a and C5aR are elevated in joints of rheumatoid and psoriatic arthritis patients, and C5aR blockade attenuates leukocyte migration to synovial fluid.

Authors:  Lars Hornum; Anker Jon Hansen; Ditte Tornehave; Marianne Scheel Fjording; Paula Colmenero; Inger Falbe Wätjen; Niels Henrik Søe Nielsen; Henning Bliddal; Else Marie Bartels
Journal:  PLoS One       Date:  2017-12-08       Impact factor: 3.240

7.  IL-4 controls activated neutrophil FcγR2b expression and migration into inflamed joints.

Authors:  Sudeepta Kumar Panda; Gustaf Wigerblad; Long Jiang; Yanek Jiménez-Andrade; Vaishnavi Srinivasan Iyer; Yunbing Shen; Sanjaykumar V Boddul; André Ortlieb Guerreiro-Cacais; Bruno Raposo; Zsolt Kasza; Fredrik Wermeling
Journal:  Proc Natl Acad Sci U S A       Date:  2020-01-24       Impact factor: 11.205
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.